July 16, 2015

Ralph Neas, president and CEO of the Generic Pharmaceutical Association, issued a statement last month criticizing the FDA at the organization’s public meeting on the Generic Drug User Free Act.

June 15, 2015

Ralph Neas, president and CEO of the Generic Pharmaceutical Association, issued a statement Monday criticizing the FDA at the organization’s public meeting on the Generic Drug User Free Act.

May 13, 2015

The FDA will review GDUFA in June. 

May 12, 2015

The OIG issued a report finding that while FDA inspection of generic manufacturers is up, those inspections are not as thorough as they could be. 

April 21, 2015

The personal care products industry supports legislation introduced Monday that would bring greater FDA oversight. 

April 16, 2015

According to the Food and Drug Administration, heart failure is a common condition that affects close to 5.1 million people in the United States. The condition arises when the heart cannot pump enough blood to meet the body’s needs. 

April 2, 2015

Alere's i Strep A test received marketing clearance from the Food and Drug Administration on Thursday. 

March 31, 2015

The director of the FDA’s Office of Generic Drugs temporarily steps down to deal with a medical issue, according to a report by the Regulatory Focus Professionals Society.

March 27, 2015

The Food and Drug Adminisration on Friday revisited the issue of supplemental applications proposing labeling changes for approved drugs and biologic products. 

March 23, 2015

The Food and Drug Administration last week warned consumers against using homeoapthic asthma remedies. 

February 26, 2015

Congress introdues legislation to protect FDA user fees from sequestration. 

February 26, 2015

The fixed-combination drug Avycaz was granted priority review by the Food and Drug Administration. 

February 24, 2015

The Food and Drug Administration is looking into enabling holders of abbreviated new drug applications to unilaterally update their generic drug product labels prior to any branded drug change. 

February 23, 2015

Combined Distributors reported that its medicine disposal product was found to exceed U.S. FDA and EPA guidelines. 

February 5, 2015

Food and Drug Commissioner Margaret Hamburg will resign from her post in March.

 

January 27, 2015

Rep. Jason Chaffetz, R-Utah, last week introduced a bill that would extend to new combination drugs containing molecules already approved by the Food and Drug Administration the same five-year market exclusivity as a drug product containing an entirely new set of active ingredients.

January 14, 2015

The Food and Drug Administration established the Office of Pharmaceutical Quality, a new division tasked with improving quality control at pharmaceutical manufacturing facilities.

 

December 22, 2014

The Food and Drug Administration has approved Zerbaxa (ceftolozane/tazobactam), a new antibacterial drug product, to treat adults with complicated intra-abdominal infections and complicated urinary tract infections.

December 5, 2014

The FDA issued a draft guidance that would provide generic companies a pathway to obtain samples of medicines requiring a Risk Evaluation and Mitigation Strategy (REMS) protocol for product testing.

December 3, 2014

The Food and Drug Administration published a final rule that sets standards for how information about using medicines during pregnancy and breastfeeding is presented in the labeling of prescription drugs and biological products.

 

December 1, 2014

The Food and Drug Administration recently issued draft guidance on key product tracing provisions of the Drug Supply Chain Security Act, which is expected to be implemented by the industry on Jan. 1, 2015. 

October 28, 2014

he Food and Drug Administration last week announced approval for Obizur for the treatment of bleeding episodes in adults with acquired hemophilia A. 

October 14, 2014

Twenty African-American and Hispanic community and health care organizations earlier this month submitted a letter to the Food and Drug Administration raising concerns that its Proposed Rule on Generic Labeling could jeopardize patient safety and access to affordable medicines. 

October 9, 2014

Congress and the sports nutrition industry independently called upon the Food and Drug Administration to act on removing an untested synthetic stimulant that was found in 12 products marketed as sports nutrition supplements.